Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 158,600 shares, a decrease of 21.7% from the February 28th total of 202,600 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average trading volume of 377,700 shares, the short-interest ratio is currently 0.4 days.

Virax Biolabs Group Stock Down 6.5 %

Virax Biolabs Group stock opened at $1.16 on Monday. The business’s 50-day moving average price is $1.65 and its 200 day moving average price is $1.91. Virax Biolabs Group has a 52 week low of $0.60 and a 52 week high of $9.00.

Institutional Trading of Virax Biolabs Group

A hedge fund recently bought a new stake in Virax Biolabs Group stock. XTX Topco Ltd bought a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned approximately 0.37% of Virax Biolabs Group as of its most recent SEC filing. Hedge funds and other institutional investors own 8.61% of the company’s stock.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.